Biogen (BIIB) – Research Analysts’ Weekly Ratings Changes

Biogen (NASDAQ: BIIB) recently received a number of ratings updates from brokerages and research firms:

• 10/12/2026 – Biogen had its “market perform” rating reaffirmed by BMO Capital Markets. They now have a $220.00 price target on the stock.
• 10/12/2026 – Biogen was upgraded by Seaport Research Partners to “outperform”.
• 10/12/2026 – Biogen was upgraded by JPMorgan Chase & Co. from “neutral” to “overweight”. They now have a $300.00 price target on the stock, up from $210.00.
• 10/9/2026 – Biogen had its price target raised by UBS Group AG from $240.00 to $270.00. They now have a “buy” rating on the stock.
• 10/8/2026 – Biogen had its price target lowered by Royal Bank Of Canada from $260.00 to $256.00. They now have an “outperform” rating on the stock.
• 9/24/2026 – Biogen was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 9/10/2026 – Biogen was given a new $242.00 price target by Stifel Nicolaus.
• 9/10/2026 – Biogen had its price target raised by HSBC Holdings plc from $165.00 to $175.00. They now have a “reduce” rating on the stock.
• 9/3/2026 – Biogen had its “overweight” rating reaffirmed by Piper Sandler. They now have a $245.00 price target on the stock, up from $225.00.
• 8/25/2026 – Biogen had its price target raised by Royal Bank Of Canada from $240.00 to $260.00. They now have an “outperform” rating on the stock.

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, amyotrophic lateral sclerosis and rare neuromuscular disorders.

Biogen’s products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich’s ataxia.